Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Trevena, Inc. (TRVN)
USD0.01
+0.00 (+0.00%)
US OTC Healthcare Biotechnology
Address
955 Chesterbrook Boulevard 19087
Chesterbrook, PA, US
Chesterbrook, PA, US
CEO
Carrie L. Bourdow
Website
trevena.com
IPO
2014-01-31
CIK 1429560 ISIN US89532E3071
Description
Trevena, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing innovative pharmaceutical solutions for individuals suffering from central nervous system disorders. Its pipeline features several promising drug candidates: OLINVYK (Oliceridine) injection: A G protein-biased mu-opioid receptor (MOR) ligand engineered to manage acute pain ranging from moderate to severe. TRV027: Aimed at addressing acute lung injury, which contributes to acute respiratory distress syndrome (ARDS) and abnormal blood clotting in patients with COVID-19. TRV250: A G protein-biased delta-opioid receptor agonist under development for the treatment of acute migraine. TRV734: A small molecule G protein-biased MOR ligand designed for the management of both moderate-to-severe acute and chronic pain. TRV045: An innovative S1P modulator focused on providing relief for chronic pain. The company has also established a partnership with Imperial College London to investigate TRV027's potential in patients afflicted with COVID-19. Trevena, Inc., founded in 2007, operates from its headquarters in Chesterbrook, Pennsylvania.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.01
+0.00 (+0.00%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
734
Beta
0.28
Float Shares
858.7K
Free Float %
99.4%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | -45.00% | +0.00% | -8.33% | -8.33% | -99.07% | -99.97% | -100.00% | -100.00% | -100.00% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (14 ratings, all time)
Buy
Price Targets & DCF
Current price
0.01
Ratings Trend (MoM)
0% Bullish
| Rating | 2025-04 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-48.18
Distress
Piotroski F-Score
3 / 9
Average
MOAT Score
2 / 10
No MOAT
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%-847.6% Q3'24: +57.2% (vs Q3'23)
-
EPS growth Biotechnology: +29.7%+58.4% ★ Q3'24: +59.2% (vs Q3'23)
-
FCF margin FCF growth · Biotechnology: +16.2%-1,141.4% Q3'24: -1,591.2% (vs Q3'23)
-
EBIT margin Biotechnology: +0.0%-1,129.2% Q3'24: -1,734.3% (vs Q3'23)
-
ROIC Biotechnology: -16.1%— Q3'24: -2,460.7% (vs Q3'23)
-
Share dilution Biotechnology: -3.4%+100.6% Q3'24: -94.0% (vs Q3'23)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-1.04× Q3'24: -1.95× (vs Q3'23)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2018 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
6.25M
est: 6.06M (+3.2%)
|
3.75M
est: 4.27M (-12.2%)
|
5.73M
est: 7.00M (-18.1%)
|
3.07M
est: 2.48M (+24.0%)
|
567.0K
est: 1.02M (-44.3%)
|
-418.0K
est: 61.3K (-781.5%)
|
3.13M
est: 443.0K (+605.4%)
|
600.0K
est.
|
3.00M
est.
|
3.00M
3.00M – 3.00M
+0.0% YoY
|
2.00M
2.00M – 2.00M
-33.3% YoY
|
366.56M
366.56M – 366.56M
+18,227.8% YoY
|
| EBITDA |
-50.62M
est: -3.63M (-1,293.1%)
|
-101.01M
est: -2.56M (-3,841.9%)
|
-28.43M
est: -4.20M (-576.8%)
|
-28.66M
est: -1.49M (-1,829.6%)
|
-51.08M
est: -610.8K (-8,263.5%)
|
-52.03M
est: -36.8K (-141,295.1%)
|
-34.95M
est: -265.8K (-13,050.5%)
|
-360.0K
est.
|
-1.80M
est.
|
-1.80M
-1.80M – -1.80M
+0.0% YoY
|
-1.20M
-1.20M – -1.20M
+33.3% YoY
|
-219.93M
-219.93M – -219.93M
-18,227.8% YoY
|
| EBIT |
-50.19M
est: -3.63M (-1,281.3%)
|
-101.26M
est: -2.56M (-3,851.5%)
|
-27.81M
est: -4.20M (-562.1%)
|
-29.04M
est: -1.49M (-1,855.6%)
|
-51.59M
est: -610.8K (-8,345.8%)
|
-52.41M
est: -36.8K (-142,333.2%)
|
-35.29M
est: -265.8K (-13,176.1%)
|
-360.0K
est.
|
-1.80M
est.
|
-1.80M
-1.80M – -1.80M
+0.0% YoY
|
-1.20M
-1.20M – -1.20M
+33.3% YoY
|
-219.93M
-219.93M – -219.93M
-18,227.8% YoY
|
| Net Income |
-50.53M
est: -9.77B (+99.5%)
|
-102.99M
est: -16.74B (+99.4%)
|
-30.78M
est: -3.50B (+99.1%)
|
-29.37M
est: -1.93B (+98.5%)
|
-51.59M
est: -2.90B (+98.2%)
|
-53.67M
est: -3.12B (+98.3%)
|
-40.29M
est: -725.84M (+94.4%)
|
-326.89M
est.
|
-12.77M
est.
|
-5.96M
-5.96M – -5.96M
+53.3% YoY
|
-4.68M
-4.68M – -4.68M
+21.4% YoY
|
-4.40M
-4.40M – -4.40M
+6.1% YoY
|
| SGA |
12.80M
est: 512.52M (-97.5%)
|
16.08M
est: 361.43M (-95.6%)
|
18.98M
est: 592.38M (-96.8%)
|
19.25M
est: 209.45M (-90.8%)
|
38.11M
est: 86.15M (-55.8%)
|
34.73M
est: 5.19M (+569.1%)
|
20.41M
est: 37.49M (-45.6%)
|
50.78M
est.
|
253.88M
est.
|
253.88M
253.88M – 253.88M
+0.0% YoY
|
169.25M
169.25M – 169.25M
-33.3% YoY
|
31.02B
31.02B – 31.02B
+18,227.8% YoY
|
| EPS |
-28.84
est: -688.89 (+95.8%)
|
-49.14
est: -1,179.81 (+95.8%)
|
-10.46
est: -246.88 (+95.8%)
|
-5.75
est: -135.94 (+95.8%)
|
-7.90
est: -204.69 (+96.1%)
|
-7.59
est: -219.92 (+96.5%)
|
-3.16
est: -51.16 (+93.8%)
|
-23.04
est.
|
-0.90
est.
|
-0.42
-0.42 – -0.42
+53.3% YoY
|
-0.33
-0.33 – -0.33
+21.4% YoY
|
-0.31
-0.31 – -0.31
+6.1% YoY
|
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-35.88M
OE per share TTM
-24.59
Owner's Yield
-379,070.34%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
329.0%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
33
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Abigail P. Johnson | 4.83M | 12.28% | — | — | 4.83M | — | IN | Delaware | 2015-06-10 | ↗ |
| 2 | Edward C. Johnson 3d | 4.83M | 12.28% | — | — | 4.83M | — | IN | Delaware | 2015-06-10 | ↗ |
| 3 | FMR LLC | 4.83M | 12.28% | 80.5K | — | 4.83M | — | HC | Delaware | 2015-06-10 | ↗ |
| 4 | Alta Partners VIII, LLC | 4.39M | 11.70% | — | 4.39M | — | 10.00 | OO | Delaware | 2014-12-15 | ↗ |
| 5 | Fidelity OTC Portfolio | 3.35M | 8.52% | 3.35M | — | — | — | IV | Delaware | 2015-06-10 | ↗ |
| 6 | 2. | 2.93M | 5.60% | — | 2.93M | — | 2.93M | IN | USA | 2016-12-12 | ↗ |
| 7 | 37-1475292 | 2.93M | 5.60% | — | 2.93M | — | 2.93M | IA | USA | 2016-12-12 | ↗ |
| 8 | Dr. Jeffrey R. Jay, M.D. | 2.93M | 5.60% | — | 2.93M | — | 2.93M | IN | USA | 2016-12-12 | ↗ |
| 9 | Alta Partners Management VIII, LLC | 2.89M | 3.50% | — | 2.89M | — | 2.89M | OO | Delaware | 2018-11-08 | ↗ |
| 10 | Daniel Janney | 2.89M | 3.50% | — | 2.89M | — | 2.89M | IN | U.S.A. | 2018-11-08 | ↗ |
| 11 | Farah Champsi | 2.89M | 3.50% | — | 2.89M | — | 2.89M | IN | U.S.A. | 2018-11-08 | ↗ |
| 12 | Guy Nohra | 2.89M | 3.50% | — | 2.89M | — | 2.89M | IN | U.S.A. | 2018-11-08 | ↗ |
| 13 | BARCLAYS GLOBAL INVESTORS, NA. | 2.88M | 4.66% | — | 2.00M | — | 2.00M | BK | Cayman Islands | 2019-02-04 | ↗ |
| 14 | (1) BlackRock, Inc. | 2.81M | 1.70% | 2.81M | — | 2.81M | — | HC | Delaware | 2022-07-08 | ↗ |
| 15 | Augustine Lawlor | 2.45M | 4.80% | — | 2.45M | — | — | IN | United States | 2016-01-29 | ↗ |
| 16 | Christopher Mirabelli, Ph.D. | 2.45M | 4.80% | — | 2.45M | — | — | IN | United States | 2016-01-29 | ↗ |
| 17 | Harold R. Werner | 2.45M | 4.80% | — | 2.45M | — | — | IN | United States | 2016-01-29 | ↗ |
| 18 | HealthCare Partners VIII, L.P. | 2.45M | 4.80% | — | 2.45M | — | — | PN | United States | 2016-01-29 | ↗ |
| 19 | HealthCare Ventures VIII, L.P. | 2.45M | 4.80% | — | 2.45M | — | — | PN | United States | 2016-01-29 | ↗ |
| 20 | James H. Cavanaugh, Ph.D. | 2.45M | 4.80% | — | 2.45M | — | — | IN | United States | 2016-01-29 | ↗ |
| 21 | John W. Littlechild | 2.45M | 4.80% | — | 2.45M | — | — | IN | United States | 2016-01-29 | ↗ |
| 22 | Armistice Capital, LLC | 784.8K | 9.99% | — | 784.8K | — | — | IA, OO | Delaware | 2023-02-14 | ↗ |
| 23 | Steven Boyd | 784.8K | 9.99% | — | 784.8K | — | — | HC, IN | United States of America | 2023-02-14 | ↗ |
| 24 | Israel A. Englander | 41.4K | 4.90% | — | 41.4K | — | 41.4K | IN | Cayman Islands | 2024-09-19 | ↗ |
| 25 | Millennium Group Management LLC | 41.4K | 4.90% | — | 41.4K | — | 41.4K | OO | Cayman Islands | 2024-09-19 | ↗ |
| 26 | Millennium Management LLC | 41.4K | 4.90% | — | 41.4K | — | 41.4K | OO | Cayman Islands | 2024-09-19 | ↗ |
| 27 | ICS Opportunities II LLC | 40.4K | 4.70% | — | 40.4K | — | 40.4K | OO | Cayman Islands | 2024-09-19 | ↗ |
| 28 | Peter Kolchinsky | — | 0.00% | — | — | — | — | IN | Massachusetts | 2016-02-16 | ↗ |
| 29 | RA Capital Healthcare Fund, L.P. | — | 0.00% | — | — | — | — | PN | Massachusetts | 2016-02-16 | ↗ |
| 30 | RA Capital Management, LLC | — | 0.00% | — | — | — | — | IA | Massachusetts | 2016-02-16 | ↗ |
| 31 | Wellington Group Holdings LLP | — | 0.00% | — | — | — | — | HC | Delaware | 2019-02-11 | ↗ |
| 32 | Wellington Investment Advisors Holdings LLP | — | 0.00% | — | — | — | — | HC | Delaware | 2019-02-11 | ↗ |
| 33 | Wellington Management Group LLP | — | 0.00% | — | — | — | — | HC | Massachusetts | 2019-02-11 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Ratio by volume
0.00
Bearish
Buys
0
Sells
15
Shares acquired
—
Shares disposed
3.5K
Cash buys
—
Cash sales
—
Net activity
-3,513
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-11-26 | Sutton Katrine | Officer | — | — | Common Stock | 0 | 0.00 | — | 942 | D | ↗ |
| 2024-10-08 | Shin Barry | Officer | F-InKind | D | Common Stock | 130 | 1.47 | 191.10 | 12,161 | D | ↗ |
| 2024-10-08 | Demitrack Mark | Officer | F-InKind | D | Common Stock | 532 | 1.47 | 782.04 | 11,363 | D | ↗ |
| 2024-10-08 | Bourdow Carrie L. | Director / Officer | F-InKind | D | Common Stock | 1,055 | 1.47 | 1.6K | 23,894 | D | ↗ |
| 2024-09-14 | Yoder Robert T | Officer | F-InKind | D | Common Stock | 487 | 5.95 | 2.9K | 5,868 | — | ↗ |
| 2024-09-14 | Shin Barry | Officer | F-InKind | D | Common Stock | 3 | 5.95 | 17.85 | 12,349 | — | ↗ |
| 2024-06-13 | Yanni Barbara | Director | A-Award | A | Stock Option (Right to Buy) | 13,700 | 0.40 | 5.5K | 13,700 | — | ↗ |
| 2024-06-13 | Phillips Anne M. | Director | A-Award | A | Stock Option (Right to Buy) | 13,700 | 0.40 | 5.5K | 13,700 | — | ↗ |
| 2024-06-13 | Nunn Jason Raleigh | Director | A-Award | A | Stock Option (Right to Buy) | 13,700 | 0.40 | 5.5K | 13,700 | — | ↗ |
| 2024-06-13 | Johnson Marvin | Director | A-Award | A | Stock Option (Right to Buy) | 13,700 | 0.40 | 5.5K | 13,700 | — | ↗ |
| 2024-06-13 | CORRIGAN MARK | Director | A-Award | A | Stock Option (Right to Buy) | 13,700 | 0.40 | 5.5K | 13,700 | — | ↗ |
| 2024-06-13 | Braunstein Scott | Director | A-Award | A | Stock Option (Right to Buy) | 13,700 | 0.40 | 5.5K | 13,700 | — | ↗ |
| 2023-12-14 | Yoder Robert T | Officer | A-Award | A | Common Stock | 92,500 | 0.61 | 56.4K | 135,806 | — | ↗ |
| 2023-12-14 | Shin Barry | Officer | F-InKind | D | Common Stock | 3,616 | 0.61 | 2.2K | 308,821 | — | ↗ |
| 2023-12-14 | Drake Patricia M. | Officer | A-Award | A | Common Stock | 50,000 | 0.61 | 30.5K | 83,913 | — | ↗ |
| 2023-12-14 | Demitrack Mark | Officer | A-Award | A | Common Stock | 185,000 | 0.61 | 112.9K | 259,817 | — | ↗ |
| 2023-12-14 | Bourdow Carrie L. | Officer | F-InKind | D | Common Stock | 7,123 | 0.61 | 4.3K | 642,923 | — | ↗ |
| 2023-12-02 | Yoder Robert T | Officer | F-InKind | D | Common Stock | 1,929 | 0.59 | 1.1K | 43,306 | — | ↗ |
| 2023-12-02 | Shin Barry | Officer | F-InKind | D | Common Stock | 3,606 | 0.59 | 2.1K | 77,437 | — | ↗ |
| 2023-12-02 | Drake Patricia M. | Officer | F-InKind | D | Common Stock | 1,835 | 0.59 | 1.1K | 33,913 | — | ↗ |
| 2023-12-02 | Demitrack Mark | Officer | F-InKind | D | Common Stock | 3,593 | 0.59 | 2.1K | 74,817 | — | ↗ |
| 2023-12-02 | Bourdow Carrie L. | Officer | F-InKind | D | Common Stock | 7,123 | 0.59 | 4.2K | 180,046 | — | ↗ |
| 2023-09-14 | Shin Barry | Officer | F-InKind | D | Common Stock | 72 | 0.70 | 50.40 | 82,473 | — | ↗ |
| 2023-07-18 | CORRIGAN MARK | Director | A-Award | A | Stock Option (Right to Buy) | 34,250 | 0.93 | 31.9K | 34,250 | — | ↗ |
| 2023-06-26 | Shin Barry | Officer | F-InKind | D | Common Stock | 722 | 0.84 | 606.48 | 82,545 | — | ↗ |
| 2023-06-15 | Yanni Barbara | Director | A-Award | A | Stock Option (Right to Buy) | 13,700 | 1.04 | 14.2K | 13,700 | — | ↗ |
| 2023-06-15 | Phillips Anne M. | Director | A-Award | A | Stock Option (Right to Buy) | 13,700 | 1.04 | 14.2K | 13,700 | — | ↗ |
| 2023-06-15 | Nunn Jason Raleigh | Director | A-Award | A | Stock Option (Right to Buy) | 13,700 | 1.04 | 14.2K | 13,700 | — | ↗ |
| 2023-06-15 | MOULDER LEON O JR | Director | A-Award | A | Stock Option (Right to Buy) | 13,700 | 1.04 | 14.2K | 13,700 | — | ↗ |
| 2023-06-15 | Johnson Marvin | Director | A-Award | A | Stock Option (Right to Buy) | 13,700 | 1.04 | 14.2K | 13,700 | — | ↗ |
| 2023-06-15 | DOUGHERTY MICHAEL R | Director | A-Award | A | Stock Option (Right to Buy) | 13,700 | 1.04 | 14.2K | 13,700 | — | ↗ |
| 2023-06-15 | Braunstein Scott | Director | A-Award | A | Stock Option (Right to Buy) | 13,700 | 1.04 | 14.2K | 13,700 | — | ↗ |
| 2023-01-06 | Yoder Robert T | Officer | A-Award | A | Common Stock | 25,000 | 0.00 | — | 46,412 | — | ↗ |
| 2023-01-06 | Shin Barry | Officer | A-Award | A | Common Stock | 50,000 | 0.00 | — | 83,267 | — | ↗ |
| 2023-01-06 | Drake Patricia M. | Officer | A-Award | A | Common Stock | 25,000 | 0.00 | — | 36,674 | — | ↗ |
| 2023-01-06 | Demitrack Mark | Officer | A-Award | A | Common Stock | 50,000 | 0.00 | — | 80,028 | — | ↗ |
| 2023-01-06 | Bourdow Carrie L. | Officer | A-Award | A | Common Stock | 100,000 | 0.00 | — | 192,074 | — | ↗ |
| 2022-12-17 | Yoder Robert T | Officer | F-InKind | D | Common Stock | 443 | 1.55 | 686.65 | 21,412 | — | ↗ |
| 2022-12-17 | Shin Barry | Officer | F-InKind | D | Common Stock | 413 | 1.55 | 640.15 | 33,267 | — | ↗ |
| 2022-12-17 | Demitrack Mark | Officer | F-InKind | D | Common Stock | 497 | 1.55 | 770.35 | 30,028 | — | ↗ |
| 2022-12-17 | Bourdow Carrie L. | Officer | F-InKind | D | Common Stock | 1,342 | 1.55 | 2.1K | 92,074 | — | ↗ |
| 2022-12-02 | Yoder Robert T | Officer | F-InKind | D | Common Stock | 753 | 3.42 | 2.6K | 21,855 | — | ↗ |
| 2022-12-02 | Shin Barry | Officer | F-InKind | D | Common Stock | 1,170 | 3.42 | 4.0K | 33,680 | — | ↗ |
| 2022-12-02 | Drake Patricia M. | Officer | F-InKind | D | Common Stock | 294 | 3.42 | 1.0K | 11,674 | — | ↗ |
| 2022-12-02 | Demitrack Mark | Officer | F-InKind | D | Common Stock | 1,121 | 3.42 | 3.8K | 30,525 | — | ↗ |
| 2022-12-02 | Bourdow Carrie L. | Officer | F-InKind | D | Common Stock | 3,560 | 3.42 | 12.2K | 93,416 | — | ↗ |
| 2022-11-10 | Drake Patricia M. | Officer | F-InKind | D | Common Stock | 632 | 2.47 | 1.6K | 11,968 | — | ↗ |
| 2022-06-28 | Shin Barry | Officer | S-Sale | D | Common Stock | 31,785 | 0.41 | 13.0K | 873,056 | — | ↗ |
| 2022-06-09 | Yanni Barbara | Director | A-Award | A | Stock Option (Right to Buy) | 100,000 | 0.00 | — | 100,000 | — | ↗ |
| 2022-06-09 | Phillips Anne M. | Director | A-Award | A | Stock Option (Right to Buy) | 100,000 | 0.00 | — | 100,000 | — | ↗ |
| 2022-06-09 | Nunn Jason Raleigh | Director | A-Award | A | Stock Option (Right to Buy) | 100,000 | 0.00 | — | 100,000 | — | ↗ |
| 2022-06-09 | MOULDER LEON O JR | Director | A-Award | A | Stock Option (Right to Buy) | 100,000 | 0.43 | 43.0K | 100,000 | — | ↗ |
| 2022-06-09 | Johnson Marvin | Director | A-Award | A | Stock Option (Right to Buy) | 100,000 | 0.00 | — | 100,000 | — | ↗ |
| 2022-06-09 | DOUGHERTY MICHAEL R | Director | A-Award | A | Stock Option (Right to Buy) | 100,000 | 0.43 | 43.0K | 100,000 | — | ↗ |
| 2022-06-09 | Braunstein Scott | Director | A-Award | A | Stock Option (Right to Buy) | 100,000 | 0.43 | 43.0K | 100,000 | — | ↗ |
| 2021-12-17 | Yoder Robert T | Officer | F-InKind | D | Common Stock | 9,711 | 0.70 | 6.8K | 565,205 | — | ↗ |
| 2021-12-17 | Shin Barry | Officer | F-InKind | D | Common Stock | 14,216 | 0.70 | 10.0K | 904,841 | — | ↗ |
| 2021-12-17 | Demitrack Mark | Officer | F-InKind | D | Common Stock | 12,408 | 0.70 | 8.7K | 791,172 | — | ↗ |
| 2021-12-17 | Bourdow Carrie L. | Director / Officer | F-InKind | D | Common Stock | 33,546 | 0.70 | 23.5K | 2,424,403 | — | ↗ |
| 2021-12-06 | Yoder Robert T | Officer | F-InKind | D | Common Stock | 22,950 | 0.65 | 14.9K | 574,916 | — | ↗ |
| 2021-12-06 | Shin Barry | Officer | F-InKind | D | Common Stock | 34,408 | 0.65 | 22.4K | 919,057 | — | ↗ |
| 2021-12-06 | Demitrack Mark | Officer | F-InKind | D | Common Stock | 30,601 | 0.65 | 19.9K | 803,580 | — | ↗ |
| 2021-12-06 | Bourdow Carrie L. | Director / Officer | F-InKind | D | Common Stock | 93,561 | 0.65 | 60.8K | 2,457,949 | — | ↗ |
| 2021-12-02 | Yoder Robert T | Officer | A-Award | A | Common Stock | 240,000 | 0.00 | — | 597,866 | — | ↗ |
| 2021-12-02 | Shin Barry | Officer | A-Award | A | Common Stock | 390,000 | 0.00 | — | 953,465 | — | ↗ |
| 2021-12-02 | Drake Patricia M. | Officer | A-Award | A | Common Stock | 100,000 | 0.00 | — | 315,000 | — | ↗ |
| 2021-12-02 | Demitrack Mark | Officer | A-Award | A | Common Stock | 390,000 | 0.00 | — | 834,181 | — | ↗ |
| 2021-12-02 | Bourdow Carrie L. | Director / Officer | A-Award | A | Common Stock | 1,250,000 | 0.00 | — | 2,551,510 | — | ↗ |
| 2021-11-10 | Drake Patricia M. | Officer | A-Award | A | Stock Option (Right to Buy) | 230,000 | 0.93 | 213.9K | 230,000 | — | ↗ |
| 2021-09-14 | Shin Barry | Officer | A-Award | A | Common Stock | 27,500 | 0.00 | — | 563,465 | — | ↗ |
| 2021-06-28 | Bourdow Carrie L. | Officer | P-Purchase | A | Common Stock | 56,200 | 1.79 | 100.5K | 1,301,510 | — | ↗ |
| 2021-06-25 | Shin Barry | Officer | F-InKind | D | Common Stock | 24,635 | 1.96 | 48.3K | 535,965 | — | ↗ |
| 2021-05-28 | Yanni Barbara | Director | A-Award | A | Stock Option (Right to Buy) | 68,577 | 1.74 | 119.3K | 68,577 | — | ↗ |
| 2021-05-28 | Phillips Anne M. | Director | A-Award | A | Stock Option (Right to Buy) | 68,577 | 1.74 | 119.3K | 68,577 | — | ↗ |
| 2021-05-28 | Nunn Jason Raleigh | Director | A-Award | A | Stock Option (Right to Buy) | 68,577 | 1.74 | 119.3K | 68,577 | — | ↗ |
| 2021-05-28 | MOULDER LEON O JR | Director | A-Award | A | Stock Option (Right to Buy) | 68,577 | 1.74 | 119.3K | 68,577 | — | ↗ |
| 2021-05-28 | DOUGHERTY MICHAEL R | Director | A-Award | A | Stock Option (Right to Buy) | 68,577 | 1.74 | 119.3K | 68,577 | — | ↗ |
| 2021-05-28 | Braunstein Scott | Director | A-Award | A | Stock Option (Right to Buy) | 68,577 | 1.74 | 119.3K | 68,577 | — | ↗ |
| 2021-03-18 | Johnson Marvin | Director | A-Award | A | Stock Option (Right to Buy) | 118,880 | 1.97 | 234.2K | 118,880 | — | ↗ |
| 2021-02-10 | Applebaum Scott | Officer | F-InKind | D | Common Stock | 21,178 | 2.85 | 60.4K | 344,022 | — | ↗ |
| 2020-12-17 | Yoder Robert T | Officer | A-Award | A | Common Stock | 141,300 | 0.00 | — | 357,866 | — | ↗ |
| 2020-12-17 | Shin Barry | Officer | A-Award | A | Common Stock | 157,000 | 0.00 | — | 560,600 | — | ↗ |
| 2020-12-17 | Demitrack Mark | Officer | A-Award | A | Stock Option (Right to Buy) | 259,100 | 2.25 | 583.0K | 259,100 | — | ↗ |
| 2020-12-17 | Bourdow Carrie L. | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 706,650 | 2.25 | 1.59M | 706,650 | — | ↗ |
| 2020-12-17 | Applebaum Scott | Officer | A-Award | A | Stock Option (Right to Buy) | 172,750 | 2.25 | 388.7K | 172,750 | — | ↗ |
| 2020-12-07 | Yoder Robert T | Officer | F-InKind | D | Common Stock | 36,688 | 2.27 | 83.3K | 216,566 | — | ↗ |
| 2020-12-07 | Shin Barry | Officer | F-InKind | D | Common Stock | 41,861 | 2.27 | 95.0K | 403,600 | — | ↗ |
| 2020-12-07 | Demitrack Mark | Officer | F-InKind | D | Common Stock | 48,557 | 2.27 | 110.2K | 271,481 | — | ↗ |
| 2020-12-07 | Bourdow Carrie L. | Director / Officer | F-InKind | D | Common Stock | 151,684 | 2.27 | 344.3K | 1,245,310 | — | ↗ |
| 2020-10-02 | Yoder Robert T | Officer | A-Award | A | Stock Option (Right to Buy) | 59,000 | 2.90 | 171.1K | 59,000 | — | ↗ |
| 2020-06-25 | Shin Barry | Officer | F-InKind | D | Common Stock | 23,539 | 1.72 | 40.5K | 445,461 | — | ↗ |
| 2020-05-13 | Yanni Barbara | Director | A-Award | A | Stock Option (Right to Buy) | 64,103 | 1.05 | 67.3K | 64,103 | — | ↗ |
| 2020-05-13 | Phillips Anne M. | Director | A-Award | A | Stock Option (Right to Buy) | 64,103 | 1.05 | 67.3K | 64,103 | — | ↗ |
| 2020-05-13 | Nunn Jason Raleigh | Director | A-Award | A | Stock Option (Right to Buy) | 64,103 | 1.05 | 67.3K | 64,103 | — | ↗ |
| 2020-05-13 | McHugh Julie | Director | A-Award | A | Stock Option (Right to Buy) | 64,103 | 1.05 | 67.3K | 64,103 | — | ↗ |
| 2020-05-13 | MOULDER LEON O JR | Director | A-Award | A | Stock Option (Right to Buy) | 64,103 | 1.05 | 67.3K | 64,103 | — | ↗ |
| 2020-05-13 | GOWEN MAXINE | Director | A-Award | A | Stock Option (Right to Buy) | 64,103 | 1.05 | 67.3K | 64,103 | — | ↗ |
| 2020-05-13 | DOUGHERTY MICHAEL R | Director | A-Award | A | Stock Option (Right to Buy) | 64,103 | 1.05 | 67.3K | 64,103 | — | ↗ |
| 2020-05-13 | Braunstein Scott | Director | A-Award | A | Stock Option (Right to Buy) | 64,103 | 1.05 | 67.3K | 64,103 | — | ↗ |
| 2020-02-10 | Applebaum Scott | Officer | A-Award | A | Common Stock | 250,000 | 0.00 | — | 250,000 | — | ↗ |
| 2019-12-12 | Yoder Robert T | Officer | A-Award | A | Common Stock | 167,000 | 0.00 | — | 253,254 | — | ↗ |
| 2019-12-12 | Shin Barry | Officer | A-Award | A | Common Stock | 194,000 | 0.00 | — | 469,000 | — | ↗ |
| 2019-12-12 | Demitrack Mark | Officer | A-Award | A | Common Stock | 213,000 | 0.00 | — | 320,038 | — | ↗ |
| 2019-12-12 | Bourdow Carrie L. | Director / Officer | A-Award | A | Common Stock | 657,000 | 0.00 | — | 925,894 | — | ↗ |
| 2019-12-02 | Yoder Robert T | Officer | F-InKind | D | Common Stock | 6,874 | 0.69 | 4.7K | 86,254 | — | ↗ |
| 2019-12-02 | Demitrack Mark | Officer | F-InKind | D | Common Stock | 8,982 | 0.69 | 6.2K | 107,038 | — | ↗ |
| 2019-12-02 | Bourdow Carrie L. | Director / Officer | F-InKind | D | Common Stock | 17,804 | 0.69 | 12.3K | 268,894 | — | ↗ |
| 2019-09-19 | Bourdow Carrie L. | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 250,000 | 1.00 | 250.0K | 250,000 | — | ↗ |
| 2019-09-18 | Yoder Robert T | Officer | A-Award | A | Stock Option (Right to Buy) | 100,000 | 1.00 | 100.0K | 100,000 | — | ↗ |
| 2019-09-18 | Demitrack Mark | Officer | A-Award | A | Stock Option (Right to Buy) | 50,000 | 1.00 | 50.0K | 50,000 | — | ↗ |
| 2019-06-25 | Shin Barry | Officer | A-Award | A | Common Stock | 275,000 | 0.00 | — | 275,000 | — | ↗ |
| 2019-06-03 | Yoder Robert T | Officer | F-InKind | D | Common Stock | 6,872 | 1.17 | 8.0K | 93,128 | — | ↗ |
| 2019-06-03 | Hamill John P. | Officer | F-InKind | D | Common Stock | 5,516 | 1.17 | 6.5K | 82,234 | — | ↗ |
| 2019-06-03 | Demitrack Mark | Officer | F-InKind | D | Common Stock | 8,980 | 1.17 | 10.5K | 116,020 | — | ↗ |
| 2019-06-03 | Bourdow Carrie L. | Director / Officer | F-InKind | D | Common Stock | 17,802 | 1.17 | 20.8K | 286,698 | — | ↗ |
| 2019-05-31 | Hamill John P. | Officer | P-Purchase | A | Common Stock | 7,500 | 1.16 | 8.7K | 87,750 | — | ↗ |
| 2019-05-16 | Yanni Barbara | Director | A-Award | A | Stock Option (Right to Buy) | 30,000 | 1.34 | 40.2K | 30,000 | — | ↗ |
| 2019-05-16 | Phillips Anne M. | Director | A-Award | A | Stock Option (Right to Buy) | 30,000 | 1.34 | 40.2K | 30,000 | — | ↗ |
| 2019-05-16 | Nunn Jason Raleigh | Director | A-Award | A | Stock Option (Right to Buy) | 30,000 | 1.34 | 40.2K | 30,000 | — | ↗ |
| 2019-05-16 | McHugh Julie | Director | A-Award | A | Stock Option (Right to Buy) | 30,000 | 1.34 | 40.2K | 30,000 | — | ↗ |
| 2019-05-16 | MOULDER LEON O JR | Director | A-Award | A | Stock Option (Right to Buy) | 30,000 | 1.34 | 40.2K | 30,000 | — | ↗ |
| 2019-05-16 | GOWEN MAXINE | Director | A-Award | A | Stock Option (Right to Buy) | 30,000 | 1.34 | 40.2K | 30,000 | — | ↗ |
| 2019-05-16 | DOUGHERTY MICHAEL R | Director | A-Award | A | Stock Option (Right to Buy) | 30,000 | 1.34 | 40.2K | 30,000 | — | ↗ |
| 2019-05-16 | Braunstein Scott | Director | A-Award | A | Stock Option (Right to Buy) | 30,000 | 1.34 | 40.2K | 30,000 | — | ↗ |
| 2019-02-01 | MOULDER LEON O JR | Director | P-Purchase | A | Common Stock | 100,000 | 1.02 | 102.0K | 100,000 | — | ↗ |
| 2019-02-01 | GOWEN MAXINE | Director / Officer | P-Purchase | A | Common Stock | 50,000 | 1.02 | 51.0K | 54,000 | — | ↗ |
| 2019-02-01 | Bourdow Carrie L. | Director / Officer | A-Award | A | Common Stock | 50,000 | 1.02 | 51.0K | 304,500 | — | ↗ |
| 2018-12-06 | Yoder Robert T | Officer | A-Award | A | Common Stock | 100,000 | 0.00 | — | 100,000 | — | ↗ |
| 2018-12-06 | Hamill John P. | Officer | A-Award | A | Common Stock | 80,000 | 0.00 | — | 80,250 | — | ↗ |
| 2018-12-06 | Demitrack Mark | Officer | A-Award | A | Stock Option (Right to Buy) | 125,000 | 0.65 | 81.3K | 125,000 | — | ↗ |
| 2018-12-06 | Bourdow Carrie L. | Director / Officer | A-Award | A | Common Stock | 250,000 | 0.00 | — | 254,500 | — | ↗ |
| 2018-09-27 | Braunstein Scott | Director | A-Award | A | Stock Option (Right to Buy) | 60,000 | 2.25 | 135.0K | 60,000 | — | ↗ |
| 2018-09-27 | Bourdow Carrie L. | Director / Officer | A-Award | A | Employee Stock Option (Right to Buy) | 335,000 | 2.25 | 753.8K | 335,000 | — | ↗ |
| 2018-08-31 | Hamill John P. | Officer | A-Award | A | Stock Option (Right to Buy) | 52,500 | 1.80 | 94.5K | 52,500 | — | ↗ |
| 2018-06-11 | Hamill John P. | Officer | — | D | Common Stock | 0 | 0.00 | — | 250 | — | ↗ |
| 2018-05-21 | Demitrack Mark | Officer | A-Award | A | Stock Option (Right to Buy) | 200,000 | 1.78 | 356.0K | 200,000 | — | ↗ |
| 2018-05-16 | Yanni Barbara | Director | A-Award | A | Stock Option (Right to Buy) | 30,000 | 1.84 | 55.2K | 30,000 | — | ↗ |
| 2018-05-16 | Phillips Anne M. | Director | A-Award | A | Stock Option (Right to Buy) | 30,000 | 1.84 | 55.2K | 30,000 | — | ↗ |
| 2018-05-16 | Nunn Jason Raleigh | Director | A-Award | A | Stock Option (Right to Buy) | 30,000 | 1.84 | 55.2K | 30,000 | — | ↗ |
| 2018-05-16 | McHugh Julie | Director | A-Award | A | Stock Option (Right to Buy) | 30,000 | 1.84 | 55.2K | 30,000 | — | ↗ |
| 2018-05-16 | MOULDER LEON O JR | Director | A-Award | A | Stock Option (Right to Buy) | 30,000 | 1.84 | 55.2K | 30,000 | — | ↗ |
| 2018-05-16 | Koppel Adam | Director | A-Award | A | Stock Option (Right to Buy) | 30,000 | 1.84 | 55.2K | 30,000 | — | ↗ |
| 2018-05-16 | DOUGHERTY MICHAEL R | Director | A-Award | A | Stock Option (Right to Buy) | 30,000 | 1.84 | 55.2K | 30,000 | — | ↗ |
| 2018-03-22 | Habib Yacoub | Officer | S-Sale | D | Common Stock | 5,000 | 1.76 | 8.8K | 0 | — | ↗ |
| 2018-02-28 | Violin Jonathan | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 65,000 | 1.79 | 116.4K | 65,000 | — | ↗ |
| 2018-02-28 | Limongelli John M | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 44,000 | 1.79 | 78.8K | 44,000 | — | ↗ |
| 2018-02-28 | Habib Yacoub | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 44,000 | 1.79 | 78.8K | 44,000 | — | ↗ |
| 2018-02-28 | Geoghegan David | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 75,000 | 1.79 | 134.3K | 75,000 | — | ↗ |
| 2018-02-28 | GOWEN MAXINE | Director / Officer | A-Award | A | Employee Stock Option (Right to Buy) | 252,500 | 1.79 | 452.0K | 252,500 | — | ↗ |
| 2018-02-28 | Cuca Roberto | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 44,000 | 1.79 | 78.8K | 44,000 | — | ↗ |
| 2018-02-28 | Bourdow Carrie L. | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 112,500 | 1.79 | 201.4K | 112,500 | — | ↗ |
| 2018-01-29 | Violin Jonathan | Officer | — | D | Common Stock | 0 | 0.00 | — | 10,192 | — | ↗ |
| 2018-01-29 | Geoghegan David | Officer | — | D | Common Stock | 0 | 0.00 | — | 0 | — | ↗ |
| 2017-08-28 | Limongelli John M | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 66,000 | 2.37 | 156.4K | 66,000 | — | ↗ |
| 2017-08-28 | Lark Michael W. | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 66,000 | 2.37 | 156.4K | 66,000 | — | ↗ |
| 2017-08-28 | Habib Yacoub | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 66,000 | 2.37 | 156.4K | 66,000 | — | ↗ |
| 2017-08-28 | GOWEN MAXINE | Director / Officer | A-Award | A | Employee Stock Option (Right to Buy) | 225,000 | 2.37 | 533.3K | 225,000 | — | ↗ |
| 2017-08-28 | Cuca Roberto | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 66,000 | 2.37 | 156.4K | 66,000 | — | ↗ |
| 2017-08-28 | Bourdow Carrie L. | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 66,000 | 2.37 | 156.4K | 66,000 | — | ↗ |
| 2017-05-25 | GOWEN MAXINE | Director / Officer | G-Gift | A | Common Stock | 403 | 0.00 | — | 195,512 | — | ↗ |
| 2017-05-17 | Yanni Barbara | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 3.08 | 46.2K | 15,000 | — | ↗ |
| 2017-05-17 | Phillips Anne M. | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 3.08 | 46.2K | 15,000 | — | ↗ |
| 2017-05-17 | Nunn Jason Raleigh | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 3.08 | 46.2K | 15,000 | — | ↗ |
| 2017-05-17 | McHugh Julie | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 3.08 | 46.2K | 15,000 | — | ↗ |
| 2017-05-17 | MOULDER LEON O JR | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 3.08 | 46.2K | 15,000 | — | ↗ |
| 2017-05-17 | Koppel Adam | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 3.08 | 46.2K | 15,000 | — | ↗ |
| 2017-05-17 | DOUGHERTY MICHAEL R | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 3.08 | 46.2K | 15,000 | — | ↗ |
| 2017-03-16 | GOWEN MAXINE | Director / Officer | G-Gift | D | Common Stock | 60,000 | 0.00 | — | 4,403 | — | ↗ |
| 2017-03-13 | GOWEN MAXINE | Director / Officer | G-Gift | A | Common Stock | 50,000 | 0.00 | — | 195,109 | — | ↗ |
| 2017-03-02 | Soergel David | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 91,000 | 4.13 | 375.8K | 91,000 | — | ↗ |
| 2017-03-02 | Limongelli John M | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 91,000 | 4.13 | 375.8K | 91,000 | — | ↗ |
| 2017-03-02 | Lark Michael W. | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 91,000 | 4.13 | 375.8K | 91,000 | — | ↗ |
| 2017-03-02 | Habib Yacoub | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 91,000 | 4.13 | 375.8K | 91,000 | — | ↗ |
| 2017-03-02 | GOWEN MAXINE | Director / Officer | A-Award | A | Employee Stock Option (Right to Buy) | 303,000 | 4.13 | 1.25M | 303,000 | — | ↗ |
| 2017-03-02 | Cuca Roberto | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 113,750 | 4.13 | 469.8K | 113,750 | — | ↗ |
| 2017-03-02 | Bourdow Carrie L. | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 91,000 | 4.13 | 375.8K | 91,000 | — | ↗ |
| 2017-02-23 | GOWEN MAXINE | Director / Officer | M-Exempt | A | Common Stock | 110,403 | 0.68 | 75.3K | 126,903 | — | ↗ |
| 2017-02-10 | Lark Michael W. | Officer | M-Exempt | A | Common Stock | 12,815 | 0.68 | 8.7K | 98,460 | — | ↗ |
| 2017-01-23 | GOWEN MAXINE | Director / Officer | G-Gift | A | Common Stock | 6,500 | 0.00 | — | 156,500 | — | ↗ |
| 2017-01-06 | Soergel David | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 55,000 | 6.61 | 363.6K | 55,000 | — | ↗ |
| 2017-01-06 | Limongelli John M | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 55,000 | 6.61 | 363.6K | 55,000 | — | ↗ |
| 2017-01-06 | Lark Michael W. | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 55,000 | 6.61 | 363.6K | 55,000 | — | ↗ |
| 2017-01-06 | Habib Yacoub | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 55,000 | 6.61 | 363.6K | 55,000 | — | ↗ |
| 2017-01-06 | GOWEN MAXINE | Director / Officer | G-Gift | A | Common Stock | 150,000 | 0.00 | — | 150,000 | — | ↗ |
| 2017-01-06 | Cuca Roberto | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 55,000 | 6.61 | 363.6K | 55,000 | — | ↗ |
| 2017-01-06 | Bourdow Carrie L. | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 55,000 | 6.61 | 363.6K | 55,000 | — | ↗ |
| 2016-11-09 | Bourdow Carrie L. | Officer | P-Purchase | A | Common Stock | 4,000 | 4.34 | 17.4K | 4,500 | — | ↗ |
| 2016-11-07 | Habib Yacoub | Officer | P-Purchase | A | Common Stock | 5,000 | 4.12 | 20.6K | 5,000 | — | ↗ |
| 2016-11-07 | GOWEN MAXINE | Director / Officer | P-Purchase | A | Common Stock | 12,500 | 4.10 | 51.3K | 16,500 | — | ↗ |
| 2016-10-20 | GOWEN MAXINE | Director / Officer | G-Gift | A | Common Stock | 10,000 | 0.00 | — | 154,000 | — | ↗ |
| 2016-10-17 | GOWEN MAXINE | Director / Officer | G-Gift | A | Common Stock | 135,025 | 0.00 | — | 135,025 | — | ↗ |
| 2016-09-29 | GOWEN MAXINE | Director / Officer | G-Gift | A | Common Stock | 130,000 | 0.00 | — | 134,000 | — | ↗ |
| 2016-05-27 | GOWEN MAXINE | Director / Officer | P-Purchase | A | Common Stock | 14,084 | 7.08 | 99.7K | 293,109 | — | ↗ |
| 2016-05-26 | GOWEN MAXINE | Director / Officer | P-Purchase | A | Common Stock | 4,000 | 7.19 | 28.8K | 279,025 | — | ↗ |
| 2016-05-18 | Yanni Barbara | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 6.98 | 104.7K | 15,000 | — | ↗ |
| 2016-05-18 | Phillips Anne M. | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 6.98 | 104.7K | 15,000 | — | ↗ |
| 2016-05-18 | Nunn Jason Raleigh | Director | A-Award | A | Director Stock Option (Right to Buy) | 15,000 | 6.98 | 104.7K | 15,000 | — | ↗ |
| 2016-05-18 | McHugh Julie | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 6.98 | 104.7K | 15,000 | — | ↗ |
| 2016-05-18 | MOULDER LEON O JR | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 6.98 | 104.7K | 15,000 | — | ↗ |
| 2016-05-18 | Koppel Adam | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 6.98 | 104.7K | 15,000 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-15.3K
Shares Outstanding
863.8K
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2022 | Carrie Bourdow President and Chief Financial Officer | 655.5K | — | — | — | 334.3K | 12.2K | 1.00M | 0.00% | ↗ |
| 2 | 2022 | Mark A. Demitrack, M.D. SVP and Chief Medical Officer | 490.5K | — | — | — | 187.6K | 12.2K | 690.3K | 0.00% | ↗ |
| 3 | 2022 | Barry Shin SVP, Chief Financial Officer | 478.0K | — | — | — | 182.8K | 9.2K | 670.0K | 0.00% | ↗ |
| 4 | 2021 | Carrie Bourdow President and Chief Financial Officer | 636.5K | — | 855.9K | — | 278.8K | 11.6K | 1.78M | 48.01% | ↗ |
| 5 | 2021 | Carrie Bourdow President and Chief Financial Officer | 630.0K | — | 855.9K | — | 278.8K | 11.6K | 1.78M | 48.18% | ↗ |
| 6 | 2021 | Barry Shin SVP, Chief Financial Officer | 464.0K | — | 300.0K | 39.0K | 152.4K | 11.6K | 967.0K | 35.06% | ↗ |
| 7 | 2021 | Barry Shin SVP, Chief Financial Officer | 445.9K | — | 300.0K | 39.0K | 152.4K | 11.6K | 948.9K | 35.72% | ↗ |
| 8 | 2021 | Mark A. Demitrack, M.D. SVP and Chief Medical Officer | 476.0K | — | 267.0K | — | 156.4K | 11.6K | 911.0K | 29.31% | ↗ |
| 9 | 2021 | Mark A. Demitrack, M.D. SVP and Chief Medical Officer | 473.3K | — | 267.0K | — | 156.4K | 11.6K | 908.3K | 29.40% | ↗ |
| 10 | 2020 | Carrie L. Bourdow President and Chief Executive Officer | 612.5K | — | 1.06M | 1.24M | 516.6K | 11.4K | 3.44M | 66.88% | ↗ |
| 11 | 2020 | Carrie Bourdow President and Chief Financial Officer | 612.5K | — | 1.06M | 1.24M | 516.6K | 11.4K | 3.44M | 66.88% | ↗ |
| 12 | 2020 | Mark A. Demitrack, M.D. SVP and Chief Medical Officer | 456.7K | — | 388.6K | 456.0K | 257.6K | 11.4K | 1.57M | 53.78% | ↗ |
| 13 | 2020 | Scott Applebaum | 336.9K | — | 456.7K | 426.8K | 215.6K | 11.4K | 1.45M | 61.04% | ↗ |
| 14 | 2020 | Barry Shin SVP, Chief Financial Officer | 425.0K | — | 353.3K | 414.5K | 239.1K | 11.4K | 1.44M | 53.20% | ↗ |
| 15 | 2019 | Carrie L. Bourdow President and Chief Executive Officer | 562.5K | — | 469.8K | 197.8K | 327.4K | 11.2K | 1.57M | 42.56% | ↗ |
| 16 | 2019 | Mark A. Demitrack, M.D. SVP and Chief Medical Officer | 440.0K | — | 152.3K | 39.6K | 187.8K | 11.2K | 830.8K | 23.09% | ↗ |
| 17 | 2019 | Robert Yoder | 345.4K | — | 119.4K | 79.1K | 134.0K | 11.2K | 689.2K | 28.81% | ↗ |
| 18 | 2018 | Maxine Gowen, Ph.D. (Former) President and Chief Executive Officer | 431.7K | — | — | — | — | 944.4K | 2.16M | 0.00% | ↗ |
| 19 | 2018 | Carrie L. Bourdow President and Chief Executive Officer | 418.3K | — | 162.5K | 1.04M | 146.7K | 11.1K | 1.78M | 67.63% | ↗ |
| 20 | 2018 | Mark A. Demitrack, M.D. SVP and Chief Medical Officer | 230.6K | — | 81.3K | 297.3K | 104.0K | 6.8K | 719.8K | 52.59% | ↗ |
| 21 | 2018 | Mark A. Demitrack, M.D. SVP and Chief Medical Officer | 230.6K | — | 81.3K | 104.0K | 104.0K | 6.8K | 719.8K | 25.73% | ↗ |
| 22 | 2018 | John M. Limongelli SVP, General Counsel Chief Administrative Officer | 354.2K | — | — | 99.7K | 99.7K | 11.1K | 672.6K | 14.83% | ↗ |
| 23 | 2017 | Maxine Gowen, Ph.D. (Former) President and Chief Executive Officer | 536.7K | — | — | 268.8K | 268.8K | 10.8K | 2.81M | 9.57% | ↗ |
| 24 | 2017 | Maxine Gowen, Ph.D. President and Chief Executive Officer | 536.7K | — | — | 1.99M | 268.8K | 10.8K | 2.81M | 70.94% | ↗ |
| 25 | 2017 | Roberto Cuca SVP and Chief Financial Officer | 348.6K | — | — | 670.6K | 111.7K | 10.8K | 1.14M | 58.74% | ↗ |
| 26 | 2017 | Carrie L. Bourdow EVP and Chief Operating Officer | 341.2K | — | — | 606.9K | 130.4K | 10.8K | 1.09M | 55.71% | ↗ |
| 27 | 2017 | Carrie L. Bourdow President and Chief Executive Officer | 341.2K | — | — | 130.4K | 130.4K | 10.8K | 1.09M | 11.97% | ↗ |
| 28 | 2017 | John M. Limongelli SVP, General Counsel Chief Administrative Officer | 342.7K | — | — | 109.2K | 109.2K | 10.8K | 1.07M | 10.21% | ↗ |
| 29 | 2016 | Maxine Gowen, Ph.D. President and Chief Executive Officer | 513.9K | — | — | 1.92M | 260.0K | 10.6K | 2.70M | 70.97% | ↗ |
| 30 | 2016 | Maxine Gowen, Ph.D. (Former) President and Chief Executive Officer | 513.9K | — | — | 260.0K | 260.0K | 10.6K | 2.70M | 9.62% | ↗ |
| 31 | 2016 | Michael W. Lark, Ph.D. SVP, Research and Chief Scientific Officer | 358.0K | — | — | 650.7K | 126.0K | 10.6K | 1.15M | 56.81% | ↗ |
| 32 | 2016 | John M. Limongelli SVP, General Counsel Chief Administrative Officer | 330.3K | — | — | 116.6K | 116.6K | 10.6K | 1.11M | 10.52% | ↗ |
| 33 | 2016 | John M. Limongelli SVP, General Counsel and Chief Administrative Officer | 330.3K | — | — | 650.7K | 116.6K | 10.6K | 1.11M | 58.72% | ↗ |
| 34 | 2016 | Roberto Cuca SVP and Chief Financial Officer | 326.3K | — | — | 520.5K | 149.2K | 10.6K | 1.01M | 51.71% | ↗ |
| 35 | 2016 | Carrie L. Bourdow President and Chief Executive Officer | 330.4K | — | — | 116.0K | 116.0K | 10.6K | 977.6K | 11.87% | ↗ |
| 36 | 2016 | Carrie L. Bourdow EVP and Chief Operating Officer | 330.4K | — | — | 520.5K | 116.0K | 10.6K | 977.6K | 53.25% | ↗ |
| 37 | 2015 | Maxine Gowen, Ph.D. President and Chief Executive Officer | 475.9K | — | — | 1.28M | 314.3K | 10.6K | 2.09M | 61.60% | ↗ |
| 38 | 2015 | Maxine Gowen, Ph.D. President and Chief Executive Officer | 475.9K | — | — | 1.28M | 314.3K | 10.6K | 2.09M | 61.60% | ↗ |
| 39 | 2015 | Michael W. Lark, Ph.D. SVP, Research and Chief Scientific Officer | 345.6K | — | — | 374.7K | 174.1K | 10.6K | 905.0K | 41.40% | ↗ |
| 40 | 2015 | Michael W. Lark, Ph.D. SVP, Research and Chief Scientific Officer | 345.6K | — | — | 374.7K | 174.1K | 10.6K | 905.0K | 41.40% | ↗ |
| 41 | 2015 | David Soergel, M.D. SVP, Clinical Development and Chief Medical Officer | 349.7K | — | — | 374.7K | 161.9K | 10.6K | 896.9K | 41.77% | ↗ |
| 42 | 2015 | Carrie L. Bourdow EVP and Chief Operating Officer | 215.4K | — | — | 537.1K | 97.9K | 22.6K | 873.0K | 61.52% | ↗ |
| 43 | 2015 | John M. Limongelli SVP, General Counsel and Chief Administrative Officer | 313.5K | — | — | 299.7K | 158.7K | 10.6K | 782.4K | 38.31% | ↗ |
| 44 | 2015 | Roberto Cuca SVP and Chief Financial Officer | 316.7K | — | — | 299.7K | 144.8K | 10.6K | 771.9K | 38.83% | ↗ |
| 45 | 2014 | Maxine Gowen, Ph.D. President and Chief Executive Officer | 432.1K | 254.6K | — | 864.5K | — | 10.4K | 1.56M | 55.36% | ↗ |
| 46 | 2014 | Maxine Gowen, Ph.D. President and Chief Executive Officer | 432.1K | 254.6K | — | 864.5K | — | 10.4K | 1.56M | 55.36% | ↗ |
| 47 | 2014 | David Soergel, M.D. SVP, Clinical Development and Chief Medical Officer | 314.7K | 150.6K | — | 271.7K | — | 10.4K | 747.4K | 36.35% | ↗ |
| 48 | 2014 | David Soergel, M.D. Chief Medical Officer and SVP, Clinical Development | 314.7K | 150.6K | — | 271.7K | — | 10.4K | 747.4K | 36.35% | ↗ |
| 49 | 2014 | Michael W. Lark, Ph.D. SVP, Research and Chief Scientific Officer | 332.8K | 136.4K | — | 247.5K | — | 10.4K | 727.1K | 34.04% | ↗ |
| 50 | 2014 | Michael W. Lark, Ph.D. SVP, Research and Chief Scientific Officer | 332.8K | 136.4K | — | 247.5K | — | 10.4K | 727.1K | 34.04% | ↗ |
| 51 | 2014 | Michael W. Lark, Ph.D. Chief Scientific Officer and SVP, Research | 332.8K | 136.4K | — | 247.5K | — | 10.4K | 727.1K | 34.04% | ↗ |
| 52 | 2014 | John M. Limongelli SVP, General Counsel and Chief Administrative Officer | 192.0K | 112.0K | — | 319.5K | — | 500.00 | 624.1K | 51.20% | ↗ |
| 53 | 2013 | Maxine Gowen, Ph.D. President and Chief Executive | 380.4K | 152.2K | — | 1.13M | — | 10.9K | 1.68M | 67.60% | ↗ |
| 54 | 2013 | Maxine Gowen, Ph.D. President and Chief Executive Officer | 380.4K | 152.2K | — | 1.13M | — | 10.9K | 1.68M | 67.60% | ↗ |
| 55 | 2013 | Maxine Gowen, Ph.D. President and Chief Executive Officer | 380.4K | 152.2K | — | 1.13M | — | 10.9K | 1.68M | 67.60% | ↗ |
| 56 | 2013 | Michael W. Lark, Ph.D. Chief Scientific Officer and Senior | 319.0K | 122.4K | — | 190.9K | — | 10.2K | 642.5K | 29.71% | ↗ |
| 57 | 2013 | Michael W. Lark, Ph.D. Chief Scientific Officer and SVP, Research | 319.0K | 122.4K | — | 190.9K | — | 10.2K | 642.5K | 29.71% | ↗ |
| 58 | 2013 | Michael W. Lark, Ph.D. SVP, Research and Chief Scientific Officer | 319.0K | 122.4K | — | 190.9K | — | 10.2K | 642.5K | 29.71% | ↗ |
| 59 | 2013 | David Soergel, M.D. Chief Medical Officer and SVP, Clinical Development | 272.1K | 104.4K | — | 152.5K | — | 10.2K | 539.2K | 28.28% | ↗ |
| 60 | 2013 | David Soergel, M.D. SVP, Clinical Development and Chief Medical Officer | 272.1K | 104.4K | — | 152.5K | — | 10.2K | 539.2K | 28.28% | ↗ |
| 61 | 2013 | David Soergel, M.D. Senior Vice President, Clinical | 272.1K | 104.4K | — | 152.5K | — | 10.2K | 539.2K | 28.28% | ↗ |
| 62 | 2012 | Maxine Gowen, Ph.D. President and Chief Executive Officer | 368.8K | 125.4K | — | — | — | 10.6K | 504.7K | 0.00% | ↗ |
| 63 | 2012 | Maxine Gowen, Ph.D. President and Chief Executive | 368.8K | 125.4K | — | — | — | 10.6K | 504.7K | 0.00% | ↗ |
| 64 | 2012 | Michael W. Lark, Ph.D. Chief Scientific Officer and Senior | 309.0K | 78.8K | — | — | — | 10.0K | 397.8K | 0.00% | ↗ |
| 65 | 2012 | Michael W. Lark, Ph.D. Chief Scientific Officer and SVP, Research | 309.0K | 78.8K | — | — | — | 10.0K | 397.8K | 0.00% | ↗ |
| 66 | 2012 | David Soergel, M.D. Chief Medical Officer and SVP, Clinical Development | 254.0K | 64.8K | — | 18.0K | — | 10.0K | 346.7K | 5.19% | ↗ |
| 67 | 2012 | David Soergel, M.D. Senior Vice President, Clinical | 254.0K | 64.8K | — | 18.0K | — | 10.0K | 346.7K | 5.19% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Carrie L. Bourdow | President, Chief Executive Officer & Chairman | 1M | female |
| Mark A. Demitrack | Senior Vice President & Chief Medical Officer | 741.3K | — |
| Robert T. Yoder | Senior Vice President, Chief Business Officer, Head of Commercial Operations & Chief Compliance Officer | 490.6K | male |
| Howard A. Rockman | Scientific Founder, Consultant and Member of Scientific Advisory Board | — | — |
| Katrine Sutton | Principal Financial Officer & principal accounting officer | — | female |
| Michael Catalano | Vice President of Marketing | — | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for TRVN
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
